GlassScriptPhysician profile
Julio A Giron
NPI 1962646653
$2,711.22
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,105 · 2022: $965 · 2023: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.53 | 2021-2023 | |
| Novo Nordisk INC | $299.39 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $289.33 | 2022-2023 | Farxiga, Breztri |
| Mylan Specialty L.P. | $211.42 | 2022-2023 | Yupelri |
| Amgen INC. | $118.31 | 2021-2023 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $110.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.44 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $83.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.77 | 2021-2023 | |
| Lilly USA, LLC | $69.19 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $54.21 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.25 | 2022 | |
| Abbott Laboratories | $41.75 | 2022-2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $39.37 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.83 | 2021-2022 | |
| Exact Sciences Corporation | $33.88 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $28.52 | 2023 | Abilify Maintena, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.50 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $23.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.78 | 2022 | |
| Alfasigma USA, INC. | $20.40 | 2021 | |
| Horizon Therapeutics Plc | $17.96 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.61 | 2021 | |
| Amarin Pharma, INC. | $17.08 | 2023 | |
| Currax Pharmaceuticals LLC | $16.84 | 2022 | |
| Lucid Diagnostics INC. | $15.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.41 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.50 | 2022 | |
| Intra-Sana Laboratories | $8.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Giron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.